ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SARS Sarossa

1.52
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Sarossa LSE:SARS London Ordinary Share JE00BKWBZV64 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.52 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Sarossa Share Discussion Threads

Showing 351 to 364 of 375 messages
Chat Pages: 15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
22/7/2020
11:41
when sellers finished will another bounce come or are some afraid of speeding ticket
bunz3
22/7/2020
11:40
still more selling
bunz3
22/7/2020
11:31
lot of selling now ,many sellers now look to be taking profits
bunz3
09/6/2020
12:03
source : Dow Jones News

Danaher Unit Unveils Sars-CoV-2/Flu A/Flu B/RSV Combo Test
Print
Alert

By Colin Kellaher



Danaher Corp.'s Cepheid unit on Tuesday said it has developed a four-in-one test to detect Sars-CoV-2, Flu A, Flu B and respiratory syncytial virus from a single patient sample.

The Sunnyvale, Calif., molecular-diagnostics company said the Xpert Xpress SARS-CoV-2/Flu/RSV is designed for use on its more than 25,000 GeneXpert Systems in place around the world, with results expected in as little as 35 minutes.

Cepheid said the test will aid global efforts in the fight against Covid-19 during the upcoming respiratory virus season, as all four infections have similar patient presentations but different treatment and management pathways, making accurate detection and differentiation critical.

Cepheid said it will pursue U.S. Food and Drug Administration approval of the test under the agency's emergency use authorization pathway.



Write to Colin Kellaher at colin.kellaher@wsj.com



(END) Dow Jones Newswires

June 09, 2020 07:41 ET (11:41 GMT)

waldron
17/4/2020
15:05
even now to watch number of buyers moving back into ncyt after shsre price drop
some exspecting rns soon

bunz3
31/8/2016
19:00
Excuse my ignorance here but if we do not take the Tender Offer, what happens to our shareholding? Do we lose all or will they be converted into something else?
lobby lud
01/7/2016
11:46
Have received circular re proposed acquisition of Ora Limited from (mainly) Richard Griffiths, Rule 9 waiver, tender offer buyback at 1.31p.

Ora Limited is valued at £6.1m (full net asset value)

Acquisition to be paid for by issuing Sarossa shares at 1.31p. This is half net asset value!!

I think this is very poor price for independent shareholders. I will vote against.

charlie
08/1/2016
11:48
PHC are down from 115 to 84 since June results and SLN are down from 305 to 150 Means the P+L will be taking a very big hit and the buyback programme of 90m at 1.72p looks a bit foolish with hindsight...with the delisting to come this is looking a bit rough. DYOR GLA
hlp_4u
08/1/2016
11:36
Now 41.617 million have scudded through at 1.31
hlp_4u
07/1/2016
15:48
A sale of 34.25 million at 1.31p is a vote of confidence NOT....with it soon to be delisted this is heading fast to sub 1p
hlp_4u
11/12/2015
13:15
Griffiths screwed the shareholders just like with ORA capital. I guess he is doing it so that he can buy back most of the shares at a heavily discounted rate. He will make a fortune on his holding, everyone else gets screwed :(

In future, I would not recommend buying any small holding where Griffiths is the majority shareholder. He seems to have a habit of screwing small shareholders.

johnsmith321
01/12/2015
13:38
No tender offer at NAV like with Jim Mellon and plethora.
johnsmith321
01/12/2015
09:35
PHC down another big chunk despite henderson topping up
hlp_4u
19/11/2015
11:44
Hi Hlp_4U,
I agree with you a revaluation is needed as SLN has halved in price since the last annual report. They bought £4M of SLN at 200p, then 300K at 240p. PHC is down 20%. GVC is also down. I think more than a £2M loss will be seen in the P+L unfortunately. I guess they may need to do more buybacks this years otherwise the NAV per share will be way down as well.

GVC will go back to 450p once the overhang of people who do not like the merger/dividend holiday go. The same thing happened at Optimal payments. Once the merger is completed, it will lead to a improvement in price as will the move to the main market.

How low (1.5p) are the BOD going to let Sarossa go before they do something. The original Sarossa cornerstone investors are way down. They need to bring in another cornerstone investor to hover up the overhang in shares otherwise this will continue down. In Adams plc, cornerston investors own 89.6%. I think they should have the same arrangement.

johnsmith321
Chat Pages: 15  14  13  12  11  10  9  8  7  6  5  4  Older

Your Recent History

Delayed Upgrade Clock